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Most kidney diseases that ultimately lead to end-stage renal
failure originate within the glomerulus and are associated
with proteinuria. Treatment options are unspecific and offer
partial cures at best because available therapies do not
primarily treat glomerular cells but rather act systemically
and thus cause many side effects. Most glomerulopathies
directly stem from injury to podocytes, cells that have a key
role in the maintenance of the glomerular filter. Thus, these
cells constitute an obvious and promising target for the
development of novel kidney-protective drugs. During the
last decade, enormous advances have been made in the
understanding of podocyte structure and function. A number
of pathways that are altered during glomerular diseases may
be targeted by novel small- and large-molecule drugs as well
as biologicals that have been identified in nephrology and
other areas of drug development. Cultured podocytes
provide a valuable model for high-throughput drug
screening assays. Furthermore, podocytes have been shown
to possess many features that make them particularly good
target cells for renal protection. This mini-review discusses
some of the most recent promising data related to potential
drug therapy for proteinuria and kidney disease through
direct podocyte targeting.
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Most kidney diseases that ultimately lead to end-stage renal
failure originate within the glomerulus and are associated
with proteinuria. Despite the significant burden they impose
to the health-care system and the urgent need for efficient
therapies, treatment options for glomerulopathies are limited
by now and offer partial cures at best. There is wide
agreement that podocytes have a central role in the
progression of glomerular diseases.1 These terminally differ-
entiated pericyte-like cells reside on the outer surface of the
glomerular basement membrane and give rise to long major
processes that branch into foot processes (FPs). FPs of
adjacent podocytes regularly interdigitade leaving between
them narrow filtration slits that are bridged by a zipper-like
structured modified adherens junction, the slit diaphragm
(SD).2 The SD forms the final barrier to protein loss into the
urinary space, which explains why podocyte injury is usually
associated with proteinuria. Although glomerular diseases are
traditionally classified into a bewildering array of entities on
the basis of clinical syndromes, etiological factors, and
pathological features, most of them show a few common
phenotypes of podocyte injury.1 The most common of these
podocyte phenotypes are FP effacement at early stages and
podocyte depletion that coincides with progression of
glomerular diseases. Podocytes are therefore an obvious and
promising target for the development of novel renoprotective
drugs. The development of podocyte-specific drugs depends
on three important premises: first, the identification of
molecular pathways involved in podocyte injury; second, the
availability of high-throughput drug screening (HTS) tools;
and third, efficient and specific drug delivery strategies to the
podocyte. As we will point out in this mini-review, all of
these premises are fulfilled due to significant recent advances
in the understanding of podocyte function and the remark-
able physiological properties of these cells.
MOLECULAR PATHWAYS IN GLOMERULAR DISEASES
During the last decade, knowledge of podocyte biology and
SD structure has advanced tremendously through genetic
studies in humans and rodents3 as well as available podocyte
cell culture systems.4 While genetic studies have contributed
invaluably to our understanding of podocyte function,
genetic defects account for only a minority of glomerular
diseases. In the following section, we will therefore focus on
pathways that have been shown to be involved in the more
common acquired human glomerular diseases. The key
molecules of these pathways may be divided into several
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categories: cell membrane receptors, ion channels, growth
factors, and proteases (Table 1 and Figure 1).
Cell membrane receptors
The transmembrane protein nephrin was the first SD-
associated protein to be identified through a genome-wide
mutation screen in families affected by Finnish-type
congenital nephrotic syndrome. Nephrin molecules from
adjacent FPs are thought to interact with each other in the
middle of the slit through their extracellular immunoglobulin
G-like domains.3 There is growing evidence that nephrin acts
in addition to its structural function as an outside-in
signaling molecule through phosphorylation by the Src
kinase Fyn, exerting both antiapoptotic stimuli via the
phosphoinositide-3 kinase (PI3K) pathway and modulating
the actin cytoskeleton via the adaptor protein Nck.5 Reduced
levels of nephrin have been found in human and experi-
mental diabetic nephropathy, which may be mediated by
protein kinase C a signaling.6 Nephrin phosphorylation was
decreased in the rat model of puromycin aminonucleoside
nephrosis preceding proteinuria and coinciding with actin
depolymerization, and in glomeruli from patients with
minimal change disease.7
B7-1 is a transmembrane protein usually expressed on the
surface of B cells and other antigen-presenting cells, where it
acts as a costimulatory molecule. An upregulation of B7-1
was found by differential-display PCR in podocytes of
a3-integrin-deficient mice that serve as a model for FP
effacement.8 Podocyte expression of B7-1 correlates with the
severity of human lupus nephritis. B7-1 induction in
podocytes is mediated by lipopolisacharide signaling through
toll-like receptor-4 and leads to reorganization of the
podocyte actin cytoskeleton and essential SD proteins. Mice
Table 1 | Pathways involved in acquired glomerular diseases
Molecular pathways Human diseases
Transmembrane receptors
Nephrin DNP, MCD
B7-1 LN
uPAR FSGS, DNP
Notch FSGS, DNP
PLA2R MN
Ion channels
TRPC6 MCD, MN
Growth factors
VEGF-A Preeclampsia
TGF-b DNP
Proteases
Cathepsin L-dynamin, synaptopodin MN, FSGS, DNP
Abbreviations: DNP, diabetic nephropathy; FSGS, focal segmental glomerulosclero-
sis; LN, lupus nephritis; MCD, minimal change disease; MN, membranous
nephropathy; TGF-b, transforming growth factor-b; TRPC6, transient receptor
potential cation channel-6; uPAR, urokinase plasminogen-activator receptor; VEGF-
A, vascular endothelial growth factor A.
Only those pathways that have been shown to be involved in acquired human
glomerular diseases are listed.
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Figure 1 |Pathways involved in acquired glomerular diseases representing targets for podocyte-specific drugs. A schematic
cross-section of a podocyte foot process with the corresponding cell body, the glomerular basement membrane, and the glomerular
endothelium is shown. Pathways involved in podocyte injury that may be drug-targeted are depicted in different colors. Sustaining nephrin
expression and phosphorylation (yellow) might contribute to both antiapoptotic signaling and actin polymerization. The B7-1 pathway
(light blue) may be targeted by (1) toll-like receptor-4 antagonists or (2) blocking the binding of B7-1 to slit diaphragm structure proteins.
Urokinase plasminogen-activator receptor (uPAR)-induced podocyte motility (violet) could be inhibited by (1) interfering with binding of
uPAR to avb3 integrin, (2) inhibiting b3 integrin activation, or (3) inhibiting binding of avb3 integrin to vitronectin. The notch pathway (dark
blue) can be targeted by (1) interfering with its upstream activation by blocking the TGF-b1 effect, (2) inhibiting g-secretase, which is
required for proteolytic receptor activation, or (3) interfering with target gene transcription. TRPC6 channels (red) may be targeted by (1)
channel blockers or (2) inhibiting their expression. The CatL pathway (green) could be targeted by (1) specifically inhibiting CatL expression
or activity, (2) shifting the equilibrium of synaptopodin toward the phosphorylated form by inhibiting calcineurin-mediated
dephosphorylation or enhancing PKA or CAMKII-mediated phosphorylation, (3) protecting synaptopodin and dynamin by compounds that
bind to the CatL cleavage site, or (4) delivering cleavage-resistant synaptopodin or dynamin mutants.
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lacking B7-1 were protected from lipopolisacharide-induced
proteinuria. This T- and B-cell-independent pathway may
have a physiological function in allowing the excretion of
pathogens and cytokines during inflammation, but leads to
glomerular disease if persistently activated.
The development of FP effacement requires a highly
dynamic reorganization of cell–matrix adhesion, which is
reflected by an increased motility of cultured podocytes.9 The
urokinase plasminogen-activator receptor has an important
function in cancer cell motility, another situation in which
cells can be hyperdynamic, allowing tissue invasion and
metastasis. Urokinase plasminogen-activator receptor was
therefore studied in the context of proteinuric diseases and
found to be significantly upregulated in glomeruli of patients
with diabetic nephropathy and FSGS, as well as in rodent
models of proteinuria.10 Urokinase plasminogen-activator
receptor is dispensible for normal renal function but required
for podocyte motility in cell culture and for the development
of FP effacement and proteinuria in vivo. These effects of
urokinase plasminogen-activator receptor are independent of
its major ligand urokinase, but require the activation of
avb3-integrin within lipid rafts and avb3-integrin-mediated
binding to high-affinity ligands such as vitronectin. This
mechanism can be antagonized in vivo with small molecule
integrin inhibitors or antibodies, leading to potent reduction
of proteinuria in a mouse model.10
The notch transmembrane receptor is part of a highly
conserved signaling pathway. Ligand binding renders
the notch receptor susceptible to metalloprotease- and
g-secretase-mediated proteolytic cleavage and release of the
intracellular domain, which subsequently translocates to the
nucleus and induces target gene transcription. The notch
pathway is crucial in podocyte development but usually not
active in the mature kidney.11 However, in experimental and
human glomerular diseases, the intracellular notch domain
(ICN) was strongly upregulated in podocytes, most likely as a
consequence of transforming growth factor-b1 (TGF-b1)-
induced transcription of the notch ligand Jagged1.12 Condi-
tional expression of ICN in mature podocytes in vivo and
in vitro induced proteinuria, FP effacement, and podocyte
apoptosis. In contrast, podocyte-specific inactivation of Rbpj,
encoding a notch transcriptional-binding partner, or treat-
ment with a g-secretase inhibitor that interferes with notch
activation, protected mice and rats from streptozotocin- and
puromycin aminonucleoside-induced glomerular damage,
respectively.
Yet another transmembrane receptor, M-type phospholi-
pase A2 receptor, has very recently been identified as target
antigen in membranous nephropathy.13 However, the
primary pathogenic role of M-type phospholipase A2
receptor in membranous nephropathy seems to be the
participation in an antigen–antibody complex, which then
leads to nocuous complement activation. The physiological
function of M-type phospholipase A2 receptor and whether
this function is affected in membranous nephropathy
remains under investigation.
Ion channels
The transient receptor potential cation channel-6 (TRPC6) is
a Ca2þ permeable ion channel expressed at the SD.
Mutations in the TRPC6 gene which increase Ca2þ
permeability were identified in families with autosomal
dominant FSGS.14,15 The interaction of TRPC6 with nephrin
and podocin,14 whose homolog mec-2 is a contributor to
mechanosensation in the worm Caenorhabditis elegans,
suggests a role of TRPC6 in a putative mechanosensor
complex at the SD that could participate in monitoring
glomerular pressure and filtration rate.16 TRPC6 expression
levels and channel function also contribute to the pathogen-
esis of acquired forms of nephrotic syndrome. Induced
expression of wild-type TRPC6 is a common feature of
human proteinuric kidney diseases, and cultured podocytes
that are exposed to complement upregulate TRPC6.17
Growth factors
Two growth factors have primarily been implicated in the
pathogenesis of glomerular diseases: TGF-b and vascular
endothelial growth factor (VEGF). TGF-b has long been
recognized as a central player in renal fibrogenesis. This
cytokine induces podocyte apoptosis leading to progressive
glomerulosclerosis in transgenic mice overexpressing TGF-
b,18 and glomerular TGF-b expression is increased in human
and experimental rodent diabetic nephropathy.19 Currently,
a neutralizing antibody against TGF-b is being tested for
the treatment of primary FSGS in a phase I study
(NCT00464321).
Podocytes, similar to pericytes of other fenestrated vascular
beds, express VEGF-A in mature glomeruli. Homozygous
podocyte-specific deletion of VEGF-A leads to severe endo-
theliosis followed by podocyte FP effacement and proteinuria,
and heterozygous mice show a similar but milder phenotype,
suggesting a ‘dose’ dependent effect of VEGF-A.20 Similar
glomerular lesions associated with thrombotic microangio-
pathy have been described in patients treated with bevacizu-
mab, a VEGF inhibitor used for cancer therapy.21 The
glomerular endothelial lesions of VEGF-A-deficient mice
further resemble the pathological lesions seen in preeclamp-
sia, and interestingly, elevated levels of placental soluble fms-
like tyrosine kinase 1, an endogenous inhibitor of VEGF, have
been found in preeclamptic patients.22 In contrast, podocyte-
specific overexpression of VEGF causes collapsing glomer-
ulopathy, the lesion seen in HIV-associated nephropathy.20
Thus, tight regulation of VEGF-A signaling seems critical for
establishment and maintenance of the glomerular filtration
barrier.
Proteases
Cathepsin L (CatL) has long been known as a potent
endoprotease primarily responsible for end-stage protein
breakdown within lysosomal compartments.23 Recently, a
cytosoplasmic variant of CatL generated by alternative
translation and devoid of the lysosomal targeting sequence
was found to be upregulated during experimental podocyte
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injury and in human glomerular diseases.24 Although
lysosomal CatL unspecifically and efficiently cleaves a variety
of proteins at a low pH, cytosolic short CatL shows
remarkable substrate and sequence specificity at a higher
pH.25 So far, two substrates of cytosolic CatL have been
identified: dynamin24 and synaptopodin,26 which both
stabilize the podocyte actin cytoskeleton and are required
for normal glomerular function. In vivo delivery of cleavage-
resistant mutant dynamin or synaptopodin or podocyte-
specific transgenic expression of a synaptopodin mutant that
lacks CatL cleavage sites protected mice from experimental
proteinuria. Of interest, synaptopodin is physiologically
protected from cleavage by CatL through phosphorylation-
dependent binding to the chaperone-like protein 14-3-3. The
calcineurin inhibitor cyclosporine blocks calcineurin-
mediated dephosphorylation of synaptopodin, and thereby
protects it from CatL-mediated cleavage.26 Thus, the
beneficial effects of calcineurin inhibitors in proteinuric
diseases may arise from a direct effect on podocytes rather
than through their immunosuppressive properties.
CULTURED PODOCYTES AS TOOLS FOR HTS
HTS has emerged as a vital technique for early-stage
discovery of disease targets and therapeutics.27 Many
biochemical assays have been miniaturized for use in the
HTS format, allowing purified protein-based, cell-based, or
even whole-organism-based (such as Drosophila melanoga-
ster, zebrafish, and C. elegans) drug discovery assays.
As described in the previous section, research in the last
decade has identified a number of podocyte proteins as
particularly suitable for therapeutic targeting. However, most
of these proteins are rather large, contain many domains, and
have a poorly defined molecular structure. In addition, some
of them do not have a known enzymatic function, but rather
serve in a structural role or as scaffolds/adaptor proteins for
dynamically assembling protein complexes and can only be
evaluated in the context of the whole cell. Furthermore, many
podocyte proteins are difficult to purify in large enough
quantities for undertaking an HTS campaign. Thus, purified
protein-based assays are not ideal for discovery of novel
podocyte-specific therapeutics. Conversely, the availability of
both murine28 and human29 podocyte cell lines make cell-
based HTS assays the most practical alternative. In addition,
the remarkable similarity of the zebrafish pronephros to
vertebrate nephrons,30 and of D. melanogaster nephrocytes31
and even C. elegans touch receptor neurons16 to vertebrate
podocytes, renders these classical model organisms poten-
tially suitable for whole-organism-based HTS.32 However,
important questions remain about how closely these organ-
isms can represent human disease processes and how reliably
such results translate to humans.
Culturing podocytes has long been hampered by the lack
of cell-type-specific markers, the rapid dedifferentiation of
podocytes in vitro and the limited ability of differentiated
podocytes to propagate in cell culture. The growing number
of identified podocyte proteins can now be used as markers
for these cells. By avoiding repeated subcultivation, differ-
entiation of primary podocytes in culture can be achieved,
but is associated with an irreversible growth arrest.33
However, using a temperature-sensitive transgene, condi-
tionally immortalized mouse28 and human29 podocyte cell
lines could be established that are able to proliferate under a
permissive temperature (331C), whereas under the nonper-
missive temperature (371C), the cells show growth arrest and
key features of podocyte differentiation. Although they
cannot fully replicate the in vivo kidney filtration barrier,
cultured podocytes provide a validated model system4 that
reliably recapitulates critical aspects of rodent and human
glomerular disease.
How can podocyte damage be visualized in vitro? As
mentioned in the introduction section, most glomerular
diseases are, regardless of their etiology, characterized by
reversible podocyte FP effacement leading to proteinuria at
early stages, and a progressive loss of podocytes leading to
glomerulosclerosis at late stages. Podocyte depletion in vivo
can be reflected by a reduced viability of cultured cells. FP
effacement involves a dynamic reorganization of attachment
to the glomerular basement membrane and of a specialized
actin-based cytoskeleton supporting the elaborate structure
of these cell processes.34 These two characteristics translate
into increased motility of cultured podocytes9 and a loss of
actin stress fibers (parallel actin bundles) in vitro, respectively.
Particularly, the latter is a very suitable read-out for drug
testing. Several substances have been used to target some of
the above discussed pathways of podocyte injury in cultured
podocytes and rodent disease models,10,24,26 and the rescue of
actin stress fibers in vitro correlated well with protection from
FP effacement and proteinuria in vivo.
In addition to such phenotypic (actin structure) and
functional (cell viability, motility) assays, reporter-based
assays can serve to identify podocyte-targeting drugs.
Yamauchi et al.35 recently used immortalized murine
podocytes that were stably transfected with a reporter gene
encoding secreted alkaline phosphatase under the control of
the nephrin promoter. The established reporter cells were
exposed to various substances, and culture media were
subjected to a secreted alkaline phosphatase assay to identify
regulators of nephrin gene expression. An inherent problem
of quantitative reporter-based assays, however, is the long
duration required for cultured podocytes to fully differenti-
ate,4 which could potentially lead to high well-to-well and
plate-to-plate variability. In contrast, imaging-based pheno-
typic assays are relatively independent of cell number per
well. To achieve higher accuracy for drug screening, multiple
measurements obtained from a single well can be combined
by high-content screening27 (Figure 2).
A typical workflow for an HTS campaign with podocytes
is depicted in Figure 3. Podocyte cell lines are grown on a
large scale under permissive conditions and then transferred
to HTS assay plates where the culture environment is
switched to nonpermissive conditions that render cells
growth arrested and fully differentiated. The differentiated
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podocytes in 96-well plates can be incubated with compound
libraries for the desired time period, and the effects of
compounds on cells can be measured using one of the
readout formats discussed above.
CLASSES OF PODOCYTE-SPECIFIC DRUGS
Podocytes can be targeted using a number of different classes
of therapeutic molecules. First, cDNA coding for proteins of
interest under the control of podocyte-specific promoters can
be delivered to podocytes in vivo through plasmid trans-
fer.10,24,26,36 Second, purified proteins may be directly
delivered to and be taken up by podocytes to replace
degraded or dysfunctional native proteins. Third, targeting
podocytes with small hairpin RNA and RNA interference
oligonucleotides for knockdown of protein expression can be
used to reduce disease-causing overexpression of podocyte
proteins. Finally, small molecules that specifically bind to
selected target proteins are effective at modulating podocyte
function, as has been shown in a number of recent studies.
Cyclo-RGDfV (Figure 4), a specific inhibitor of integrin
avb3, ameliorates proteinuria in mouse models of nephrotic
syndrome by directly targeting the upregulated integrin avb3
on podocytes.10 Similarly, the calcineurin inhibitor cyclos-
porine reduces proteinuria by specifically stabilizing synap-
topodin in podocytes.26 Furthermore angiotensin-converting
enzyme inhibitors, and angiotensin II receptor blockers37 as
well as glucocorticoids38 have recently been shown to directly
act on podocytes in addition to their antihypertensive and
immunosuppressive properties, respectively.
Cell-based HTS assays can be used to discover potential
podocyte-targeting therapeutics from any of these classes of
molecules. Screening chemical libraries against cultured
podocytes remains the most promising approach for
discovering novel podocyte-specific therapeutics because
uptake of DNA, RNA, and protein by terminally differen-
tiated podocytes in culture is relatively inefficient and
a b
c d
Figure 2 |Phenotypic podocyte assays used for high-content
screening (HCS). Cultured podocytes can be used in HCS assays
for automated detection of cellular morphology and stress fiber
formation in a high-throughput environment. (a) An HCS
captured image from a well of a 96-well plate with podocytes
stained with phalloidin to detect actin-stress fibers. (b) Same
image as in panel a stained with Cell Mask Blue (to stain cell nuclei
and cytoplasm). (c) An overlay of images in panels a and b. (d) An
overlay of automatically calculated cellular boundaries that can be
used in measuring various cellular characteristics (such as cell
number, cell size, and intensity of stress fibers per cell) on the raw
image (a) from the 96-well plate.
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Figure 3 | Schematic of a workflow for a primary drug screen with cultured podocytes. Cultured podocytes are grown under permissive
conditions at 331C to allow for proliferation. Next, cells are transferred to 96-well HTS microtiter plates and allowed to differentiate under
nonpermissive conditions at 371C. Fully differentiated podocytes are incubated with chemical compound libraries, and the effect of
compounds on cells is measured using a variety of cell-based readout assays. These detection assays include high-content imaging to
detect changes in cellular phenotypes, measurement of homogenous changes in absorbance, fluorescence- or luminescence-based gene
reporter assays as well as determination of changes in cell viability and cellular function, such as adhesion and motility.
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variable,39 while small molecules can easily penetrate the
podocyte cell membrane. However, ‘biologics’ (DNA, RNA,
proteins, and antibodies) are valuable tools in deciphering
the exact molecular signaling pathways and especially
antibodies against cell-surface receptors hold considerable
therapeutic promise.
PODOCYTES QUALIFY FOR EFFICIENT TARGETED DRUG
DELIVERY
Any pharmacological compound designed to specifically
target pathways of podocyte injury needs to be deliverable to
podocytes in vivo with sufficient efficiency and specificity.
Most drugs reach their site of action through the circulation
after being injected or absorbed in the gut. Therefore, the
perfusion of an organ is a critical pharmacokinetic determi-
nant. The kidney is perfused by 25% of the total cardiac
output while accounting for only 0.5% of total body weight.
Hence, the perfusion rate of the kidney, amounting to
350ml/min per 100 g tissue, is 70 times higher than that of
the remaining body. Approximately 20% of the plasma
volume perfusing the kidneys is filtered into Bowman’s space.
Thus, podocytes are virtually flushed by 180 l of plasma
ultrafiltrate per day. In contrast, drugs targeting other organs
must usually leave the capillary bed by paracellular diffusion
through endothelial cell junctions or by transcellular
pinocytosis and reach their site of action by further diffusion
through the interstitium. There remains controversy about
the permeability of the glomerular layers before the podocyte
SD. However, the fenestrated glomerular endothelium is
certainly by far more permeable to macromolecules than
most other vascular beds throughout the body. The successful
use of gene24 and antibody10 delivery to podocytes in mice
shows that the glomerular endothelium and the glomerular
basement membrane are sufficiently permeable for the
delivery of these macromolecules to podocytes in vivo.
Once having reached the podocytes, a podocyte-specific
drug will need to be taken up by these cells efficiently (in the
case of intracellularly acting compounds) and bind its
molecular target with high affinity in order not to be lost
into the urine. Affinity can be optimized using secondary
drug screening assays with libraries of subclasses of com-
pounds identified in a primary HTS, or through molecular
modeling. Small molecular compounds with an intracellular
target usually diffuse readily through the cell membrane,
whereas specific drug delivery strategies are required for
macromolecules, such as nucleic acids and proteins. During
the last decade, substantial progress has been made in the
design of new technologies to improve cellular uptake of
therapeutic compounds, including the use of cell-penetrating
peptides.40 Cell-penetrating peptides allow the cytosolic
delivery of macromolecules including small hairpin RNA
and proteins. While some of the carrier molecules transport
their cargoes directly through the plasma membrane, others
use the cell’s endocytosis machinery. In this respect, it is
important to point out that the podocyte possesses an
efficient endocytosis machinery41 capable to endocytose
albumin42 and immunoglobulin G,43 which can likely be
exploited therapeutically.
CONCLUSIONS
Significant advances have recently been made in the under-
standing of podocyte biology and the pathophysiology of
glomerular diseases, providing promising target pathways
for drug discovery. The ability to culture and manipulate
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Figure 4 |Cyclo-RGDfV as an example of a small molecule targeting podocytes. (a) Chemical structure of the anti-integrin avb3 drug
cyclo-RGDfV. (b) Three-dimensional crystal structure of the extracellular domains of integrin avb3 (shown as a ribbon model with av-chain in
blue and b3-chain in red) bound to cyclo-RGDfV (green, shown as a CPK model). Bound metal ions are shown as gray spheres. Models a and
b are based on the study by Dechantsreiter et al.44 and Xiong et al.,45 respectively. Cyclo-RGDfV has been successfully used to treat
proteinuria in the lipopolysaccharide-mouse model.10
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podocytes in vitro can be implemented in modern HTS
assays to identify compounds that specifically interact with
podocyte proteins. Furthermore, podocytes are particularly
amenable to efficient and specific drug delivery due to their
anatomical location and physiological properties. Several
molecular pathways involved in glomerular diseases have
already been successfully targeted in rodent disease models.
Taken together, there is justified hope that novel podocyte-
targeting pharmaceuticals will be developed and applied to
patients in the near future.
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